Less than a year since the start of the COVID-19 pandemic, ten vaccines against SARS-CoV-
2 have been approved for at least limited use, with over sixty others in clinical trials. This …

A multitude of new agents for the treatment of hematologic malignancies has been
introduced over the past decade. Hematologists, infectious disease specialists, stem cell …

Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-
19 disease and mortality. The goal of this study was to determine the efficacy of COVID-19 …

Methods We examined 44 consecutive patients with CLL who received two doses of mRNA
vaccine (BNT162b2 or mRNA-1273) between 1/2/21 and 3/12/21 and were tested for anti …

B-cell chronic lymphocytic leukaemia (CLL) is associated with immunosuppression and
patients are at increased clinical risk following SARS-CoV-2 infection. Covid-19 vaccines …

Vaccinations are effective in preventing infections; however, it is unknown if patients with
chronic lymphocytic leukemia (CLL) who are treatment naïve (TN) or receiving Bruton …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

Patients with haematological malignancies are at high risk of infection because of various
mechanisms of humoral and cell-mediated immune deficiencies, which mainly depend on …

Bruton´ s tyrosine kinase (BTK) inhibitor (BTKi) s block the B-cell receptor (BCR) signaling
cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant …

Immunocompromised patients with hematologic malignancies are more susceptible to
COVID-19 and at higher risk of severe complications and worse outcomes compared with …